Business Context and Reporting Period
This Form 8-K was filed by Bond Laboratories, Inc. (referred to in metadata as FITLIFE BRANDS, INC.) on September 4, 2013, with the report date of September 10, 2013. The filing details a material definitive agreement and a planned recapitalization of the company's capital structure.
Key Financial Metrics and Obligations
- Debt Financing: The Company executed a Term Loan Agreement with U.S. Bank for $2.6 million.
- Loan Terms: Interest rate of 3.6% per annum; maturity date of August 15, 2018.
- Collateral: The loan is secured by a continuing security interest in substantially all of the Company's assets, including its interest in its wholly-owned subsidiary, NDS Nutrition, Inc.
- Guarantee: Repayment is guaranteed by NDS Nutrition, Inc.
- Liquidity and Cash Flow: The filing text does not provide specific values for current revenue, profit, operating cash flow, or existing liquidity positions.
Material Changes and Capital Structure Actions
The proceeds from the new term loan are designated to finance a recapitalization plan announced on September 10, 2013. Key actions include:
- Series B Preferred Stock: Redemption of all outstanding shares of 10% Cumulative Perpetual Series B Preferred Stock.
- Series C Preferred Stock: Partial redemption of half the issued shares at par plus accrued dividends; conversion of the remaining shares and accrued dividends into common stock at $0.25 per share.
- Warrants: Exchange and cancellation of 2,500,000 warrants for 625,000 shares of common stock.
- Reverse Stock Split: A proposed 10-for-1 reverse split of common stock, pending FINRA review and acceptance.
Outlook, Risks, and Management Commentary
Management intends to use the new debt facility to reduce preferred stock obligations and restructure equity. The filing includes a standard disclaimer regarding forward-looking statements, noting that plans and expectations are subject to significant risks and uncertainties. The success of the recapitalization is contingent upon regulatory approvals (FINRA) and the consummation of the specific transactions outlined.
Investor Verification Checklist
- Verify the final approval status of the 10-for-1 reverse stock split by FINRA.
- Confirm the exact redemption price and accrued dividend amounts for the Series C Preferred Stock.
- Review the impact of the new $2.6 million debt obligation on the company's future interest expense and debt covenants.
- Monitor subsequent 8-K filings for the consummation of the Series B and Series C redemptions.
- Assess the dilution effect of converting remaining Series C shares and exchanging warrants into common stock.